DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 203 filers reported holding DENALI THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,225 | -18.9% | 225 | -28.3% | 0.00% | -100.0% |
| Q1 2024 | $6,443 | -53.5% | 314 | -51.4% | 0.00% | 0.0% |
| Q4 2023 | $13,863 | +181.1% | 646 | +170.3% | 0.00% | 0.0% |
| Q3 2023 | $4,931 | -74.0% | 239 | -62.8% | 0.00% | -50.0% |
| Q2 2023 | $18,945 | +81.1% | 642 | +41.4% | 0.00% | +100.0% |
| Q1 2023 | $10,460 | +5.9% | 454 | +27.9% | 0.00% | 0.0% |
| Q4 2022 | $9,873 | +9.7% | 355 | +28.2% | 0.00% | -50.0% |
| Q3 2022 | $9,000 | +28.6% | 277 | +24.2% | 0.00% | +100.0% |
| Q2 2022 | $7,000 | 0.0% | 223 | +9.3% | 0.00% | 0.0% |
| Q1 2022 | $7,000 | -74.1% | 204 | -66.6% | 0.00% | -75.0% |
| Q4 2021 | $27,000 | +1250.0% | 611 | +1697.1% | 0.00% | – |
| Q1 2021 | $2,000 | – | 34 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $404,042,000 | 54.41% |
| Bratton Capital Management, L.P. | 953,035 | $19,785,000 | 29.05% |
| Flagship Pioneering Inc. | 8,005,747 | $166,199,000 | 7.19% |
| Casdin Capital, LLC | 400,000 | $8,304,000,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $91,561,000 | 0.65% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,595 | $469,000 | 0.37% |
| MARK ASSET MANAGEMENT LP | 70,532 | $1,464,000 | 0.34% |
| Artal Group S.A. | 400,000 | $8,304,000 | 0.34% |
| PIER 88 INVESTMENT PARTNERS LLC | 27,650 | $574,000 | 0.24% |
| WASATCH ADVISORS LP | 996,147 | $20,680,000 | 0.20% |